|MAKO MEDICAL ADDS COST-EFFECTIVE, MASS SCREENING ANTIGEN TEST|
|By GLOBE NEWSWIRE|
|Tuesday, 23 February 2021 06:43|
Raleigh, North Carolina, Feb. 23, 2021 (GLOBE NEWSWIRE)
Raleigh, North Carolina, Feb. 23, 2021 (GLOBE NEWSWIRE) -- MAKO Medical Laboratories, a national reference laboratory and leader in COVID-19 testing, is offering a new, cost-effective mass screening antigen test to help fight the pandemic. The new MAKO Antigen test utilizes the DiaSorin LIAISON® SARS-CoV-2 Ag high-throughput antigen test for COVID-19, which allows for an additional option to detect the virus in people suspected of having COVID-19 by their healthcare provider.
"Our MAKO team is excited to partner with Diasorin to bring this highly sensitive antigen test to the masses," said Josh Arant, COO, MAKO Medical. "With a sensitivity of 97.1% and a specificity of 100%, utilizing nasal and nasopharyngeal swabs, MAKO can turn results around in less than 24 hours with a capacity to run over 100,000 tests per day."
The MAKO Antigen test allows for the identification of SARS-CoV-2 N protein antigen, which is generally detectable during the acute phase of infection. The test combines a highly accurate in-lab antigen test with a platform capable of supporting large-scale screening of the active virus of COVID-19. This cost-effective test will help with mass screenings and determine whether a person diagnosed with the virus continues to have and carry the virus.
"DiaSorin's platform demonstrates the next level of understanding for COVID-19 cases, and it allows our team to further our partnership with health officials across the country as a one-stop laboratory service provider," said Arant.
A College of American Pathologists (CAP) accredited laboratory with more than 5 million COVID-19 tests performed since April 2020, MAKO Medical uses industry-leading testing assays and new Next Generation Sequencing (NGS) research panels to identify COVID-19 cases, as well as to detect the virus's mutations and variants. To date, the MAKO team has detected more than 160 COVID-19 variant cases across nine of the thirty-eight states it conducts testing in, including instances of the B.117, B.1351, and L452R variants.
About MAKO Medical
Founded in 2014, MAKO Medical is a diagnostics partner for businesses, physicians, urgent care facilities, and hospitals around the United States. MAKO Medical has recruited chemists and scientists to provide industry-leading innovation. MAKO Medical Laboratories' methods and assays are validated for reproducibility, precision, and accuracy. MAKO Medical invests heavily in state-of-the-art instrumentation and technology. To learn more, visit makomedical.com.
Seth Palmer MAKO Medical 919-653-7816 [email protected]